Trial Profile

A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALT 801 (Primary) ; Cisplatin; Gemcitabine
Indications Urethral cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Altor BioScience Corporation

Most Recent Events

04 Oct 2016 According to Altor BioScience Corporation media release, Status changed from active, no longer recruiting to completed.
11 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2017.
24 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com